Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement

Article

Oxford Expression Technologies (OET, Oxford, UK) and Eden Biodesign (Liverpool, UK) have signed a co-marketing agreement.

Oxford Expression Technologies (OET, Oxford, UK) and Eden Biodesign (Liverpool, UK) have signed a co-marketing agreement. Under the terms of the agreement, OET will offer its customers access to Eden Biodesign’s process development, clinical trial cGMP manufacturing, and analytical development services. In return, Eden Biodesign’s customers will have access to OET’s wide range of baculovirus capabilities to meet their individual protein expression requirements.

Recent Videos
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.